Objective: Here, we generated conditional, heart-specific transgenic mice with both gain-and loss-of-function for IP 3 receptor signaling to examine its hypertrophic growth effects following pathological and physiological stimulation.
C
ardiac hypertrophy occurs as an adaptive response to various cardiovascular diseases such as hypertension, valvular insufficiency, ischemic heart disease, infectious agents, or mutations in sarcomeric genes. 1 Ca 2ϩ underlies excitationcontraction coupling (ECC), and it serves as a second messenger to induce cardiac hypertrophy, in part, by activating select Ca 2ϩ -dependent reactive signaling proteins such as calcineurin, calmodulin-dependent kinase (CaMK)II, and protein kinase C. 2, 3 However, it remains unknown how Ca 2ϩ activates these hypertrophic signaling effectors in the heart given ECC-mediated Ca 2ϩ fluxing that bathes the entire cytoplasm of a cardiac myocyte. 4 One possibility is that specialized pools of Ca 2ϩ have evolved that are temporally and spatially distinct from the cytoplasmic Ca 2ϩ transient in ECC. For example, CaMKII is activated in cardiomyocytes by a perinuclear Ca 2ϩ pool associated with the inositol 1,4,5 trisphosphate (IP 3 ) receptor. 5 IP 3 is a second messenger generated by hydrolysis of membrane lipid phosphatidyl-inositol 4,5-bisphosphate by phospholipase (PL)C in response to GPCR activation associated with growth factors and neuroendocrine agonists. 6 Once generated, IP 3 causes Ca 2ϩ release from intracellular stores by binding the IP 3 receptor (IP 3 R), an intracellular Ca 2ϩ release channel embedded in the sarcoplasmic reticulum (SR) and nuclear envelope. Cardiac hypertrophy has been associated with increased PLC activity and increased generation of IP 3 . 7, 8 Moreover, expression of IP 3 Rs is increased in both human and animal models of heart failure, suggesting that this form of Ca 2ϩ release may be associated with pathology. 9, 10 The IP 3 R family consists of 3 genes 11 : IP 3 R1, IP 3 R2, and IP 3 R3. IP 3 R2 is thought to be the most prominent gene expressed in the heart, 12, 13 and its deletion in gene-targeted mice abolished positive inotropy and spontaneous Ca 2ϩ release in atrial myocytes caused by endothelin (ET)-1 stimulation. 13 Even though ventricular myocytes express much lower levels of IP 3 Rs than atrial myocytes, these receptors, in some reports, can alter Ca 2ϩ release and predispose to arrhythmia. 14 -16 Although the IP 3 Rs can affect Ca 2ϩ release, it has not been possible to determine their necessity in regulating the cardiac hypertrophic response because all 3 receptor genes are expressed in the heart, complicating a gene-targeting approach, not withstanding lethality issues in IP 3 R1-null mice. Here, we generated transgenic mice with IP 3 R2 overexpression and the inhibitory IP 3 -sponge protein, demonstrating for the first time that the IP 3 R functions as a hypertrophic effector in vivo.
Methods

Generation of Transgenic Mice
cDNAs encoding mouse IP 3 R2 and recombinant Flag-tagged IP 3 -sponge protein 17, 18 were cloned into the murine inducible ␣-myosin heavy chain (␣-MHC) promoter expression vector (gift from Dr Jeffrey Robbins, Children's Hospital, Cincinnati, Ohio). 19 G␣q transgenic mice were kindly provided by Dr Gerald Dorn II. 20 NFAT-luciferase reporter transgenic mice and calcineurin A␤-null mice (CnA␤ Ϫ/Ϫ ) were reported previously. 21, 22 To reduce strain effects the CnA␤-null mice (C57BL/6) were backcrossed 6 generations into the IP 3 R2 (FVB/N) background. Mice were given doxycycline (Sigma, St Louis, Mo) at 1 g/L in the drinking water for 3 weeks to shut down protein expression from the inducible transgenes. All animal procedures were approved by the Institutional Animal Care and Use Committee of Cincinnati Children's Hospital Medical Center.
Western Blot Analysis
Western blot analysis for mouse ventricle homogenates were performed as previously reported. 23 Antibodies included IP 3 R2, G␣q, and ␣-tubulin (Santa Cruz Biotechnology), GAPDH (Research Diagnostics Inc, Flanders, NJ), and Flag M2 monoclonal (Sigma). Chemifluorescent detection was performed with the Vistra ECF reagent (Amersham Pharmacia Biotech, Piscataway, NJ) and scanned with a Storm 860 PhosphoImager (Molecular Dynamics, Piscataway, NJ).
Isolation of Adult Cardiomyocytes and Ca
2؉ Measurements
Only Ca 2ϩ -tolerant cardiomyocytes were selected for Ca 2ϩ measurements, as reported previously. 24 Ca 2ϩ transients were measured using Fluo-4, as described previously, 25 or using Fura-2 fluorescence ratio at room temperature using a Delta Scan dual-bean spectrofluorophotometer (Photon Technology, Birmingham, NJ), at an emission wavelength of 510 nm and excitation of 340 and 380 nm. The amplitude (⌬340/380 nm ratio) of the Ca 2ϩ transients was measured before and after exposure to freshly prepared 100 nmol/L ET-1 (Calbiochem) or with 1 mol/L forskolin alone or in combination with 40 nmol/L ET-1. Arrhythmias were classified by 3 or more extrasystolic Ca 2ϩ release events over a 15-minute recording period following previously reported criteria. 16 
RT-PCR, Luciferase Assay, Immunohistochemistry, and Histological Analysis
RT-PCR was performed as described previously. 26 For histological analysis, hearts were collected at the indicated times, fixed in 10% formalin containing PBS, and embedded in paraffin. Myocyte cross-sectional areas were analyzed in slides stained with wheat germ agglutinin-FITC. 24 Immunohistochemistry on adult myocytes was performed as described previously using an IP 3 R2 antibody (Abcam) and ␣-actinin (Sigma). 27 
Echocardiography, Invasive Hemodynamics, and Surgical Models
Mice were anesthetized with isoflurane, and echocardiography was performed using a Hewlett Packard 5500 instrument with a 15-MHz microprobe as described previously. 23 Invasive hemodynamics in the closed-chest mouse with a 1.4F Millar catheter was performed as described previously. 28 Transverse aortic constriction (TAC) to induce cardiac pressure overload hypertrophy was described previously. 23 Pressure gradients across the constriction were measured by Doppler echocardiography as described previously. 29 Alzet miniosmotic pumps (no. 2002; Alza Corp, Mountain View, Calif) containing isoproterenol (Iso) (60 mg/kg per day), angiotensin II (2 mg/kg per day), or PBS were surgically inserted in 2-month-old mice as described previously. 26 Swimming for 20 days as a model of exercise-induced cardiac hypertrophy was described previously. 21, 24 
Statistical Analysis
All results are presented as meansϮSEM. Statistical analysis was performed using SigmaPlot11.0 software for unpaired t test (for 2 groups) and 2-way ANOVA (for 4 to 6 groups).
Results
Generation of IP 3 Receptor Transgenic Mice
To determine the role of IP 3 -mediated Ca 2ϩ release in the heart, we generated inducible, cardiac-specific transgenic mice expressing the mouse type-2 IP 3 R. Responder transgenic lines were crossed with driver transgenic mice encoding the tetracycline transactivator (tTA) protein (double transgenic [DTG] ) and a "high" (3.11) and "low" (4.9) line were selected based on Western blot analysis ( Figure 1A ). TAC induced a 2.4-fold increase in IP 3 R2 protein expression in the mouse heart, and relative to this, lines 3.11 and 4.9 showed 12-and 5-fold more protein expression, respectively. To examine the reliability of the inducible system, doxycy- cline (Dox) was administered to the low-expressing DTG mice, causing near complete extinguishment of IP 3 R2 expression ( Figure 1B ). Importantly, ventricular myocytes isolated from adult IP 3 R2 DTG mice showed a significant increase of amplitude in the Ca 2ϩ transient and extrasystolic Ca 2ϩ transients after ET-1 stimulation, whereas no effect was observed in tTA control ventricular myocytes ( Figure 1C ).
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Immunocytochemistry from DTG ventricular myocytes showed that the IP 3 R2 was localized in a distinct sarcomeric pattern that is consistent with the SR ( Figure 1D ). Because of low endogenous expression, little IP 3 R2 protein was detectable in control tTA ventricular myocytes ( Figure 1D ; the IP 3 R2 antibody used also reacted with a nucleoplasmic protein in all samples, masking the nuclear envelope localized IP 3 R2).
High-Expressing IP 3 R2 Transgenic Mice Display Cardiac Hypertrophy
Both high and low IP 3 R2 DTG mice (no Dox) developed mild cardiac hypertrophy by 3 months of age ( Figure 2A ). Consistent with this phenotype, reexpression of the hypertrophyrelated genes atrial natriuretic factor and skeletal ␣-actin were observed in the hearts of high-expressing DTG mice ( Figure  2B ). DTG mice demonstrated normal values of baseline ventricular performance by echocardiography ( Figure 2C ), baseline myocyte Ca 2ϩ transient amplitudes, and SR Ca 2ϩ content in isolated cells (data not shown). However, a more sensitive approach using a Millar catheter showed that highexpressing IP 3 R2 DTG mice had a reduced contractile response to dobutamine infusion, although no change in baseline function was observed ( Figure 2D ). Myocyte Ca 2ϩ responses following Iso stimulation were also reduced, suggesting desensitization of ␤-adrenergic receptors (data not shown). Thus, outside of a mild deficit in functional reserve, high-expressing DTG mice showed no greater signs of heart disease past 10 months of age.
To further investigate the hypothesis that the IP 3 R2 was involved in hypertrophic signaling, high-expressing DTG and littermate tTA mice were subjected to 2 weeks of TAC to induce hypertrophy. Indeed, high-expressing DTG mice at 9 to 10 weeks of age displayed enhanced cardiac hypertrophy after TAC with equivalent pressure gradients across the constrictions ( Figure 2E and data not shown). Assessment of myocyte cross sectional areas also showed significantly more hypertrophy in IP 3 R2 DTG mice compared with tTA controls ( Figure 2F ).
As previously reported, ␤-adrenergic stimulation activates protein kinase (PK)A, leading to IP 3 R2 phosphorylation and sensitized Ca 2ϩ release to IP 3 . 30 Consistent with these observations, 2 weeks of Iso infusion with Alzet minipumps produced more cardiac hypertrophy in DTG mice compared with tTA controls (Figure 2G and 2H). To further examine the impact of increased IP 3 R2 expression downstream of GPCR signaling, we crossed IP 3 R2 DTG mice with transgenic mice overexpressing G␣q, a direct PLC effector and disease inducer. 20 As predicted, combined IP 3 R2 and G␣q overexpression exacerbated the hypertrophic phenotype and pathology, such as greater increases in ventricle weight normalized to body weight and decreased fractional shortening assessed by echocardiography ( Figure 2I and 2J) . The inset in Figure 2I shows that G␣q protein was overexpressed by Ϸ3-fold with the transgene when crossed into the IP 3 R2 DTG background. Taken together, these results suggest that IP 3 R2 expression can enhance cardiac hypertrophy and disease downstream of multiple pathological stimuli.
Low-Expressing IP 3 R2 Transgenic Mice Show Increased Cardiac Hypertrophy to Iso and Exercise
We also repeated our entire analysis with low-expressing IP 3 R2 DTG mice. Remarkably, 2 weeks of TAC stimulation in low-expressing IP 3 R2 DTG mice failed to show augmented cardiac hypertrophy compared to tTA control mice ( Figure  3A and 3B). Pressure gradients across the aortic constriction were not different between the 2 groups of TAC mice (data not shown). However, low-expressing IP 3 R2 DTG mice did show significantly greater cardiac hypertrophy following 2 weeks of Iso infusion, similar to the enhancement observed in high-expressing DTG mice ( Figure 3C and 3D ). In addition, the enhanced hypertrophic response in low-expressing DTG mice caused by ␤-adrenergic stimulation was reversed when the transgene was shut down by administration of Dox ( Figure 3E and 3F). These results in lower-expressing DTG mice suggest that IP 3 R-augmented Ca 2ϩ release activated by ␤-adrenergic receptor stimulation is likely a physiologically important aspect of signaling in cardiac myocytes.
We also used a model of physiological cardiac hypertrophy caused by forced swimming exercise over 20 days in IP 3 R2 DTG and tTA control mice. Surprisingly, both low-and highexpressing IP 3 R2 DTG mice demonstrated significantly greater cardiac hypertrophy after 20 days of swimming compared with tTA controls (Figure 3G and 3H) . Forced swimming likely induces a concomitant catecholamine response in the mice, which would be consistent with the enhanced hypertrophy profile associated with Iso infusion, collectively suggesting that IP 3 -mediated Ca 2ϩ release is of physiological relevance in regulating cardiac hypertrophy to select stimuli.
The results presented above suggested that G␣q and cAMP pathways might converge on the IP 3 R to regulate hypertrophy. To further address this assertion, we measured Ca 2ϩ transients and arrhythmia in adult myocytes from IP 3 R2 DTG mice using forskolin in combination with low dose ET-1 (40 nmol/L). We were not able to use Iso given the ␤-receptor desensitization discussed above, but forskolin elevated cAMP and increased the Ca 2ϩ transient and induced mild arrhythmia ( Figure I in the Online Data Supplement, available at http://circres.ahajournals.org). Whereas low dosage ET-1 was without effect, when used in combination with forskolin, even greater Ca 2ϩ release and arrhythmias were observed in adult myocytes from IP 3 R2 DTG mice (Online Figure I) .
Inhibition of IP 3 Signaling Reduces Cardiac Hypertrophy to Iso and Angiotensin II Infusion
Here, we generated inducible IP 3 -sponge transgenic mice to reduce endogenous IP 3 signaling in the adult mouse to examine its necessity in programming hypertrophy. The IP 3 -sponge is a truncated and soluble IP 3 receptor that binds free IP 3 with exceedingly high affinity. 18 Two responder transgenic lines were obtained, although only the higher expressing line (line 22.3) was analyzed ( Figure 4A ). To determine the effectiveness of IP 3 -chelating activity in vivo, we crossed IP 3 -sponge mice with high-expressing IP 3 R2 DTG mice, after which adult myocytes were isolated and stimulated with ET-1. Importantly, triple transgenic mice (tTA driver, IP 3 -sponge, and IP 3 R2 responder transgenes) showed no loss in protein expression for either the IP 3 -sponge or IP 3 R2 ( Figure 2B ). Myocytes from IP 3 R2 high-overexpressing mice showed a robust increase in Ca 2ϩ transients and arrhythmic events, which was completely blocked by the IP 3 -sponge ( Figure  4C and 4D) . Thus, targeted expression of the IP 3 -sponge in the mouse heart eliminates functional IP 3 -dependent Ca 2ϩ release in isolated ventricular myocytes.
To assess the impact of IP 3 signaling inhibition on pressureoverload hypertrophy, IP 3 -sponge DTG and tTA mice were subjected to TAC stimulation. Consistent with the results observed in low-expressing IP 3 R2 DTG mice, IP 3 -sponge overexpression showed no ability to reduce the cardiac hypertrophic response after 2 weeks of TAC stimulation compared with tTA controls (Figure 4E and 4F) . However, IP 3 -sponge DTG mice showed significantly less hypertrophy following 2 weeks of Iso infusion ( Figure 4G and 4H) . No reduction in fractional shortening was noted over 2 weeks of Iso infusion, and levels of induced fibrosis were similar between tTA and IP 3 -sponge DTG hearts (Online Figure II) . We also observed that the hypertrophic response caused by angiotensin II infusion was significantly reduced in IP 3 -sponge DTG mice ( Figure 4I ). Taken together, these results indicate that IP 3 signaling plays a necessary role in select forms of hypertrophic stimulation in adult mouse heart (see Discussion).
Calcineurin Signaling Underlies IP 3 -Regulated Hypertrophy
Calcineurin is Ca 2ϩ /calmodulin-dependent protein phosphatase that functions as a central regulator of cardiac hypertrophy, in part, by activating a transcription factor family known as NFAT (nuclear factor of activated T cells). 31 Here, we hypothesized that the calcineurin/NFAT pathway might respond to IP 3 R signaling in mediating the cardiac hypertrophic response. To address this issue, high and low IP 3 R2 DTG mice were crossed with NFAT-luciferase reporter transgenic mice, showing a 3.5-and 2.4-fold increase in NFAT activity, respectively, compared with tTA mice at 8 weeks of age ( Figure 5A) . Expression of the IP 3 -sponge did not affect NFAT-luciferase activity at baseline in the heart ( Figure 5A ). To extend these results and determine whether calcineurin was necessary for IP 3 R2 enhanced hypertrophy, we crossed the IP 3 R2 responder and tTA driver transgenes into the CnA␤-null background. CnA␤ ϩ/ϩ (wild-type) controls were also generated from the same backcross. Importantly, cardiac expression level of IP 3 R2 protein directed by the transgene was similar between the CnA␤ Ϫ/Ϫ and CnA␤ ϩ/ϩ backgrounds ( Figure 5B) . Remarkably, the augmented hypertrophy profile observed in IP 3 R2 DTG mice following 2 weeks of Iso stimulation was blocked in the CnA␤ Ϫ/Ϫ background but, once again, was significantly augmented in the wild-type background ( Figure 5C and 5D) . Collectively, these results indicate that calcineurin/NFAT serve as a downstream effector of IP 3 R-mediated Ca 2ϩ signaling in the heart.
Discussion
IP 3 Rs are intracellular ligand-gated Ca 2ϩ release channels that are activated by IP 3 binding, where they function downstream of growth factors and GPCR signaling events. 6 The physiological role of Ca 2ϩ release from the IP 3 R in ventricular myocytes has been a controversial issue, with some reports suggesting no effect on ECC, whereas others have observed a small but significant effect on spontaneous Ca 2ϩ release in the form of sparks and enhanced Ca 2ϩ transients. 15, [32] [33] [34] In atrial myocytes, IP 3 -mediated Ca 2ϩ release appears to be a more prominent event that modulates ECC and SR Ca 2ϩ release, 35, 36 likely because of higher endogenous IP 3 R expression levels. 15, 34 Consistent with these reports, transgene-directed overexpression of IP 3 R2 in ventricular myocytes had a prominent effect on ECC and even arrhythmia on ET-1 stimulation, further suggesting that IP 3 Rs are positioned within the junctional SR, where they can affect ryanodine receptor (RyR) activity.
To affect ECC, the IP 3 Rs need to be positioned within the proper functional domains of the SR. Previous analysis of this issue demonstrated that IP 3 R2 is enriched at the nuclear envelop, which is contiguous with the SR/ER network in adult cardiac myocytes. 12, 37, 38 However, localization to the nuclear envelope should not affect ECC but, instead, appears to control nuclear Ca 2ϩ signaling 39 and a local pool of CaMKII. 5 In addition to the nuclear envelope, the IP 3 Rs are prominently localized to the SR, in similar regions as the RyR. 16 Indeed, immunohistochemistry of adult myocytes from IP 3 R2 DTG overexpressing mice versus tTA controls unequivocally showed IP 3 R2 localization within the entire expanse of the SR and around the nucleus.
Another aspect of the controversy surrounding a functional role for IP 3 Rs in cardiac myocytes is that generation of IP 3 appears to be relatively weak compared with other cell types. 40, 41 For example, cardiomyocytes from mouse or human display only a 1.5-to 2-fold activation of PLC in response to ␣ 1 -adrenergic receptor stimulation, achieving a level of Ϸ30 nmol/L. [42] [43] [44] [45] However, phosphorylation of IP 3 R2 by PKA sensitizes the channel and enhances IP 3 -mediated Ca 2ϩ release at lower IP 3 concentrations. 30 In addition to this mechanism, Iso stimulation in cultured cardiomyocytes enhances IP 3 generation through an ET-1 paracrine/autocrine signaling circuit. 38 ␤-Adrenergic stimulation also enhances SR Ca 2ϩ levels and sensitizes the RyR, together leading to augmented Ca 2ϩ release. In support of this contention, low levels of ET-1, which did not change Ca 2ϩ release or induce arrhythmia, did synergistically increase arrhythmia when forskolin was also used to elevate cAMP. We also believe that physiological exercise-induced cardiac hypertrophy, which appears to elicit a strong fear response in mice, augmented IP 3 R Ca 2ϩ release through an associated ␤-adrenergic costimulation effect. These concepts are also consistent with the vast array of neurohumoral mediators that underlie pathological cardiac hypertrophy and failure, where multiple G␣q-coupled receptor agonists likely synergize with cAMP elevation afforded by ␤-receptor signaling to induce pathology.
Interestingly, only the high IP 3 R2 DTG line showed augmented cardiac hypertrophy with pressure-overload stimulation. In contrast, the low overexpressors and the IP 3 -sponge mice each failed to show an effect with pressureoverload stimulation. The simplest interpretation of these results is that a requirement for endogenous IP 3 Rs is easily bypassed with extreme hypertrophic stimulation, such as afforded by pressure overload. Indeed, TRPC channels are also activated in pressure-overloaded hearts, where they could easily compensate and provide local Ca 2ϩ entry in the absence of IP 3 R signaling to maintain calcineurin activation. 46 In contrast, Iso infusion engages a more restricted set of signaling pathways, such as PKA activation through elevated cAMP. As discussed earlier, ␤-adrenergic/PKA stimulation uniquely primes IP 3 R2 activation and Ca 2ϩ release, possibly explaining why Iso infusion in low-expressing DTG mice and in IP 3 -sponge mice demonstrated a positive effect versus tTA control mice.
The increase in Ca 2ϩ release mediated by IP 3 Rs at the level of the SR could induce the hypertrophic response through a number of different signaling mechanisms. Our working hypothesis is that IP 3 R Ca 2ϩ release generates a local Ca 2ϩ signaling effect at the level of the T-tubular-SR junctional complex. Indeed, calcineurin is anchored at the Z-lines to calsarcin and ␣-actinin, in immediate proximity to the SR junctions. 47 Calcineurin was also shown to respond to IP 3 -mediated Ca 2ϩ release from a perinuclear/nuclear location in neonatal cardiomyocytes to induce hypertrophy. 38 Consistent with these results, we observed prominent NFAT activation in IP 3 R2 DTG hearts and that deletion of CnA␤ blocked the ability of Iso to enhance hypertrophy through the IP 3 R2 transgene. This IP 3 R-dependent release of Ca 2ϩ at the Ttubular-SR junctions could also stimulate RyR Ca 2ϩ leak, providing additional regional Ca 2ϩ elevations to affect calcineurin. Thus, antagonism of the IP 3 R may be a clinically relevant target, because it might reduce both arrhythmia and hypertrophic growth propensity. 
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